UK-based dermatology company SkinBioTherapeutics (AIM: SBTX) is to acquire the issued share capital of Dermatonics, a specialist in innovative topical and dermatological products in the skincare and woundcare space.
The initial sum is £1.68 million ($2.14 million) plus £1.25 million earn-out over three years, in a cash-free and debt-free acquisition.
SkinBio’s shares dropped 11.8% to 13.02 pence following the announcement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze